Ocular Therapeutix to Present Detailed Phase 3 AXPAXLI Trial Results at Macula Society Meeting
OCUL sits 55% above its 52-week low of $5.785.
Summary
Ocular Therapeutix announced it will make available detailed Phase 3 clinical trial results for AXPAXLI (OTX-TKI) for wet age-related macular degeneration at the 49th Macula Society Annual Meeting.
Key Events · Product Development and Regulatory · OCUL
-
Phase 3 Trial Results Presentation
Ocular Therapeutix will present detailed results from its SOL-1 Phase 3 superiority clinical trial of AXPAXLI (OTX-TKI) for wet age-related macular degeneration at the 49th Macula Society Annual Meeting.
-
Regulation FD Disclosure
The company will make the presentation slides available on its corporate website under the Investors section at 4:15 pm ET on February 27, 2026.
Analysis · OCUL · Life Sciences
This 8-K signals a significant upcoming catalyst for Ocular Therapeutix, as it announces the imminent release of detailed Phase 3 clinical trial results for AXPAXLI in wet AMD. For a biotech company, successful Phase 3 data is crucial for regulatory approval and future commercialization, especially given the company's recent financial performance showing increased net losses. Investors will closely monitor the presentation for the full data, which could significantly impact the company's valuation and long-term prospects.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 28.9% of the 1666 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OCUL was trading at $8.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $5.79 to $16.44. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.